Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Agios Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2026 was MXN1,438 Mil.
Agios Pharmaceuticals's quarterly Total Liabilities
declined
from Dec. 2025 (MXN1,874.59 Mil) to Mar. 2026 (MXN1,368.23 Mil) but then
increased
from Mar. 2026 (MXN1,368.23 Mil) to Jun. 2026 (MXN1,437.85 Mil).
Agios Pharmaceuticals's annual Total Liabilities
increased
from Dec. 2023 (MXN2,140.44 Mil) to Dec. 2024 (MXN2,549.46 Mil) but then
declined
from Dec. 2024 (MXN2,549.46 Mil) to Dec. 2025 (MXN1,874.59 Mil).
Agios Pharmaceuticals Total Liabilities Related Terms
Agios Pharmaceuticals Total Liabilities Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Agios Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of MXN1,438 Mil mean?
Agios Pharmaceuticals (MEX:AGIO) has a Total Liabilities of MXN1,438 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Total Liabilities too high?
Agios Pharmaceuticals' current Total Liabilities is MXN1,438 Mil. Overall, Agios Pharmaceuticals has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Total Liabilities compare to BHVN and VRDN?
Agios Pharmaceuticals' Total Liabilities of MXN1,438 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Total Liabilities is MXN1,438 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (MEX:AGIO) has a current Total Liabilities of MXN1,438 Mil. The stock's GF Value™ is MXN4,160.80, compared to a current price of MXN1,222.00 — trading 70.6% below its estimated fair value. The current Total Liabilities is MXN1,438 Mil. Agios Pharmaceuticals' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Agios Pharmaceuticals (MEX:AGIO), the current Total Liabilities is MXN1,438 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (MEX:AGIO) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN1,222.00 is trading 70.6% below its estimated GF Value™ of MXN4,160.80.
Key valuation signals for MEX:AGIO:
Total Liabilities: MXN1,438 Mil
GF Value™: MXN4,160.80 vs. price of MXN1,222.00 (70.6% below fair value)
No single metric tells the full story. See the MEX:AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
47GF Score
Get the complete analysis for MEX:AGIO
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AGIO has been successfully added to your 
